
Nikkomycin Z demonstrated favorable safety and pharmacokinetics in healthy adults. Administered in oral doses (250–750 mg), it showed dose-dependent plasma concentrations, with peak levels of 3.70–6.89 mg/L at 2.3–3.0 hours. AUC values increased with dose, though bioavailability plateaued at higher levels. The drug was well tolerated over 14 days without serious side effects, supporting its continued development for treating coccidioidomycosis.
Like
Save
Share